Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Vivos Therapeutics reports revenue growth and strategic expansion plans

Vivos Therapeutics showed revenue growth and improved gross profit margins in Q3 2024. Despite challenges in net loss and cash burn, the company is optimistic about achieving positive cash flow and expanding its market presence through strategic alliances.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today announced it plans to release its third quarter 2023 financial results after market close on Tuesday, November 14, 2023.

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that today it has closed a $4 million private placement previously announced on October 31, 2023.

Vivos Therapeutics Closes $4 Million Private Placement

Vivos Therapeutics (NASDAQ:VVOS) has announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common shares effective at the start of trading on Friday, October 27, 2023.  The medical technology company said among other considerations, the reverse split is intended to bring Vivos into compliance with the $1.00 minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market, and to make the prevailing prices of its shares more attractive to a broader group of institutional investors.

Vivos Therapeutics reveals 1-for-25 reverse stock split

1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October 27, 2023 1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October 27, 2023

Vivos Therapeutics Announces Reverse Stock Split

Vivos Therapeutics (NASDAQ:VVOS) announced it has signed a United States-wide distribution agreement for its oral appliances with Lincare, a leading supplier of in-home respiratory therapy products and services to about 1.8 million patients.  The company noted that the distribution agreement comes on the heels of a distribution pilot with Lincare and will allow Vivos to engage with durable medical equipment (DME) companies in the United States.

Vivos Therapeutics inks distribution agreement for its oral devices with Lincare

Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Better sleep is better health, period. But for many people, it's not that easy.

Vivos Therapeutics can help you get a better sleep (really)

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics (NASDAQ:VVOS) Inc has announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine.  The medical technology company said study participants with moderate to severe obstructive sleep apnea (OSA) will be randomly assigned to either treatment with Vivos' DNA appliance or CPAP (continuous positive airway pressure), the current industry standard for OSA treatment.

Vivos Therapeutics to kick off clinical trial at Stanford Medicine

Randomized controlled clinical trial using Vivos' DNA Oral Appliance Therapy to study the DNA's impact on OSA versus CPAP Randomized controlled clinical trial using Vivos' DNA Oral Appliance Therapy to study the DNA's impact on OSA versus CPAP

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Vivos Therapeutics (NASDAQ:VVOS) shares continued to make gains on Thursday morning after the developer of oral appilances for the treatment of sleep-related disorders announced it has entered into an exclusive distribution agreement with Dubai-based Noum, a company that distributes products to healthcare providers and hospital networks treating patients with obstructive sleep apnea in the Middle East – North Africa (MENA) region. Shares of Vivos gained 15.5% in pre-market trade to US$0.35 after closing up almost 64% higher on Wednesday on the news it has entered into partnerships with Ormco and ON Demand Orthodontist.

Vivos Therapeutics shares gains continue on Noum collaboration

Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024 LITTLETON, Colo., Oct. 05, 2023 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders, today announced it has entered into an exclusive distribution agreement with NOUM DMCC (“Noum”), a Dubai-based company focused on diagnostic testing and treatment product distribution for healthcare providers and hospital networks treating obstructive sleep apnea patients throughout the Middle East-North Africa (MENA) region.

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Vivos Therapeutics (NASDAQ:VVOS) has announced two strategic agreements that will expand its current product line of oral appliances for the treatment of breathing-related sleep disorders and are expected to create near-term revenue opportunities. Shares of Vivos jumped on the news, up 55% at US$0.29 in pre-market trade on Wednesday.

Vivos Therapeutics announces strategic agreements with Ormco and On Demand Orthodontist

New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

Vivos Therapeutics (NASDAQ:VVOS) said it will welcome best-selling author James Nestor to headline its Fifth Annual Breathing Wellness Conference. Nestor is the author of the best-selling book, Breath, in which he chronicles his own journey of discovery and healing.

Vivos Therapeutics previews upcoming conference featuring headline speaker James Nestor

Vivos Attracts Wide Group of Experts in Dental and Medical Disciplines With a Shared Vision to Treat the Millions of Patients Suffering with Breathing-Related Sleep Disorders Vivos Attracts Wide Group of Experts in Dental and Medical Disciplines With a Shared Vision to Treat the Millions of Patients Suffering with Breathing-Related Sleep Disorders

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

After losing some value lately, a hammer chart pattern has been formed for Vivos Therapeutics, Inc. (VVOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher

Cisco Systems

Synopsys

Wolfspeed

Cisco Systems (NASDAQ:CSCO) delivered a strong 4Q earnings report that came in ahead of expectations on Wednesday after market close, sending its shares 2.2% higher in extended trading.  The communications firm reported revenue of $15.2 billion for the quarter compared to the $15.05 billion expected by the Street, while its adjusted earnings per share came in at $1.14 versus $1.06 expected.

The Afterhours: Cisco, Wolfspeed, Synopsys, Vivos

Vivos Therapeutics (NASDAQ:VVOS) said its cost-cutting initiatives drove a significant reduction in its net loss during the second quarter when compared to the same period in 2022.  For the three months ended June 30, 2023, the company reduced its net loss by 21% to $1.5 million when compared to the year-ago quarter.

Vivos Therapeutics cost-cutting measures pay off in 2Q

Operating Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date, Reflecting Cost Cutting Initiatives

Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update

LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, today announced that the Company intends to release its second quarter 2023 financial results after market close today, Wednesday, August 16, 2023.

Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call

LITTLETON, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, today announced it will reschedule its conference call to review its financial results for the second quarter ended June 30, 2023, previously scheduled for today at 5:00 p.m. (Eastern Time). Further details for the second quarter financial results conference call will be provided in a subsequent announcement.

Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call

LITTLETON, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, today announced it plans to release its second quarter 2023 financial results after market close on Monday, August 14, 2023.

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2023 Earnings Conference Call June 8, 2023 5:00 PM ET Company Participants Julie Gannon - IR Kirk Huntsman - Chairman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - ROTH Capital Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2023 Earnings Conference Call.

News for Vivos Therapeutics Stock (VVOS)